These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20959524)

  • 1. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.
    Bozik ME; Mather JL; Kramer WG; Gribkoff VK; Ingersoll EW
    J Clin Pharmacol; 2011 Aug; 51(8):1177-85. PubMed ID: 20959524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
    Cheah BC; Kiernan MC
    IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
    Cudkowicz M; Bozik ME; Ingersoll EW; Miller R; Mitsumoto H; Shefner J; Moore DH; Schoenfeld D; Mather JL; Archibald D; Sullivan M; Amburgey C; Moritz J; Gribkoff VK
    Nat Med; 2011 Nov; 17(12):1652-6. PubMed ID: 22101764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
    Rodríguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
    J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.
    Hirawat S; Welch EM; Elfring GL; Northcutt VJ; Paushkin S; Hwang S; Leonard EM; Almstead NG; Ju W; Peltz SW; Miller LL
    J Clin Pharmacol; 2007 Apr; 47(4):430-44. PubMed ID: 17389552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
    Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
    J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.
    Gribkoff VK; Bozik ME
    CNS Neurosci Ther; 2008; 14(3):215-26. PubMed ID: 18801114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Merschman SA; Strohmaier KM; Ramael S; Lasseter KC; Stone JA; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Feb; 83(2):293-9. PubMed ID: 17713476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
    Ishizuka H; Yoshiba S; Okabe H; Yoshihara K
    J Clin Pharmacol; 2010 Nov; 50(11):1319-29. PubMed ID: 20145259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans.
    Cotreau MM; Warren S; Ryan JL; Fleckenstein L; Vanapalli SR; Brown KR; Rock D; Chen CY; Schwertschlag US
    J Clin Pharmacol; 2003 Oct; 43(10):1108-15. PubMed ID: 14517193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
    Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
    Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects.
    Ahmed T; Sharma P; Gautam A; Varshney B; Kothari M; Ganguly S; Moehrle JJ; Paliwal J; Saha N; Batra V
    J Clin Pharmacol; 2008 Feb; 48(2):166-75. PubMed ID: 18199893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.